Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22776936 | 0.90 | CYP2C19 (0.41) | CYP2C19CYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL20140638 | 0.89 | CYP2C19 (0.40) | CYP2C19CYP3A4CYP2D6CYP2C9MAPT | |
| Hydrochloric Acid SCHEMBL21496926 | 0.89 | CYP3A4 (0.40) | CYP2C19CYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL19436606 | 0.88 | CYP3A4 (0.45) | CYP2C19CYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL20140580 | 0.87 | CYP3A4 (0.39) | CYP2C19CYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL25348687 | 0.86 | CYP3A4 (0.41) | CYP2C19CYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL2845209 | 0.83 | OPRM1 (0.41) | CYP2C19CYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL422879 | 0.83 | MAPT (0.46) | CYP2C19CYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL16699574 | 0.83 | CYP3A4 (0.44) | CYP2C19CYP3A4CYP2D6CYP2C9MAPT | |
| SCHEMBL30943025 | 0.82 | ALDH1A1 (0.39) | CYP2C19CYP3A4CYP2D6CYP2C9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538526-B1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-17 | — | — | US | disclosed |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3704112-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3538526-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2018089355-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | CYP2C19 1466/4885CYP3A4 1749/4885CYP2D6 2639/4885 |
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | CYP2C19 1158/4885CYP3A4 1366/4885CYP2D6 2453/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | CYP2C19 1348/4885CYP3A4 1435/4885CYP2D6 2562/4885 |
| US-11286252-B2 | Alkene spirocyclic compounds as farnesoid X receptor modulators | NR1H2, NR1H4, NR1H3 | CYP2C19 973/4885CYP3A4 375/4885CYP2D6 948/4885 |
| US-11014922-B2 | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | CYP2C19 1726/4885CYP3A4 1893/4885CYP2D6 2688/4885 |
| US-20210179599-A1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H2, NR1H4, NR1H3 | CYP2C19 973/4885CYP3A4 375/4885CYP2D6 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.